Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - rabies virus (inactivated) strain wistar (pm/wi 38-1503-3m) - powder and solvent for suspension for injection in pre-filled syringe - rabies, inactivated, whole virus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - rabies virus (inactivated) - vaccine

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - rabies virus (inactivated) - rabies virus (inactivated) 0 vaccine - vaccine

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur - rabies virus inactivated - powder and solvent for suspension for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabies virus, quantity: 2.5 iu - injection, powder for - excipient ingredients: albumin; neomycin - idications as at 12 july 2004: post exposure immunisation against rabies. pre-exposure immunisation in persons at special risk of contracting rabies.

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - inactivated rabies virus - powder and solvent for solution for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

United States - English - NLM (National Library of Medicine)

grifols usa, llc - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies vaccine and hyperrab s/d should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. hyperrab s/d should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. recommendations for use of passive and active immunization after exposure to an animal suspected of having rabies have been detailed by the u.s. public health service advisory committee on immunization practices (acip). [19] every exposure to possible rabies infection must be individually evaluated. the following factors should be considered before specific antirabies treatment is initiated: carnivorous wild animals (especially skunks, foxes, coyotes, raccoons, and bobcats) and bats are the animals most commonly infected with rabies and have caused most of the indigenous cases of human rabies

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi pasteur europe s.a. - rabies virus (inactivated) ; albumin human 50 mg - powder and solvent for solution for injection - rabies virus, inactivated - rabies, inactivated, whole virus

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - rabies virus (inactivated) >= 2 iu/dose - suspension for injection - rabies virus, inactivated - rabies virus - cattle; dog; horse; cat; sheep

United States - English - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually an immunization series is initiated and completed with 1 vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv.4,11 preexposure vaccination: see table 1 and dosage and administration. preexposure vaccination consists of 3 doses of rabavert 1.0 ml given intramuscularly (deltoid region), 1 each on days 0, 7, and 21 or 281 (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see dosage and administration: postexposure prophylaxis of previously im